Viatris Inc.

- The transcript does not mention any current or planned fundraising through debt or equity. - The company emphasizes significant financial flexibility with more than $2.5 billion of cash available for deployment in 2026. - Capital allocation is focused on balanced deployment: returning capital to shareholders via dividends and share repurchases and investing in business growth and business development. - No indication of plans for issuing new equity or taking on new debt was provided during the call. - The company is prioritizing disciplined execution, cost management, and operational efficiency to support growth without new fundraising.

- The company is making significant investments to expand manufacturing capacity, particularly to support sustainable growth for products like Creon. - They continue to invest in their commercial platforms, notably in China, including e-commerce capabilities which have shown strong sales growth. - Capital allocation remains disciplined, balancing shareholder returns (dividends and share repurchases) with strategic investments in the business to support sustainable growth. - Business development focuses on in-market, accretive assets aligned with company capabilities to strengthen long-term growth. - The company is on track to deliver cost savings from an enterprise-wide strategic review and is reinvesting some of these savings to support future growth. - There is significant cash expected in 2026 (over $2.5 billion) to deploy across priorities, including capital investments and pipeline advancement. - Launches and pipeline development (innovative and generic products) imply ongoing strategic investments in R&D and commercialization.

- Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. - Growth is expected to ramp up into 2027-2029, supported by multiple pipeline catalysts and product launches. - Strong momentum in Greater China with 18% year-over-year growth, driven by cardiovascular portfolio and e-commerce expansion. - Continued growth expected from launches in the U.S., including fast-acting meloxicam and XULANE LO contraceptive patch. - Generic portfolio progress with FDA approvals and launches planned (e.g., generic Abilify Maintena in the U.S. by year's end). - Innovative drugs selatogrel and cenerimod Phase III programs on track, with potential longer-term growth impact. - Supply constraints in some portfolios being mitigated; forecast incorporates these risks. - Business development focused on in-market accretive assets to fuel sustainable growth alongside internal pipeline.

- Viatris delivered 3% revenue growth and 10% adjusted EBITDA growth in Q1 2026, showing strong momentum. - The company targets 4% organic growth by 2030, starting with a strong 3% growth in Q1; growth expected to ramp in 2027-2029. - Adjusted EPS was $0.59 per share in Q1, with confidence in meeting or exceeding full-year expectations. - Cost savings programs are on track to deliver $120 million in savings for 2026, supporting margin expansion. - Operating leverage and disciplined cost management to improve EBITDA margins in 2027-2028. - Key pipeline product launches (e.g., fast-acting meloxicam, XULANE LO patch) anticipated to accelerate revenue growth. - Free cash flow strong, with more than $2.5 billion expected for 2026, providing capital flexibility for growth and shareholder returns. - Overall focus on disciplined execution to drive sustainable revenue, profits, and EPS growth over the coming years.

- The transcript does not explicitly mention a current or expected orderbook or pending orders by Viatris. - However, the company highlights strong commercial execution, particularly in Greater China and Japan, indicating a robust demand environment. - Several key product launches and regulatory approvals are expected in 2026, including: - Fast-acting meloxicam (NDA accepted, approval expected by year-end). - Low-dose estrogen transdermal contraceptive patch (XULANE LO) with expected PDUFA date by July 30, 2026. - Phentolamine ophthalmic solution with an expected PDUFA date of October 17, 2026. - Japan market includes recent approval for EFFEXOR in generalized anxiety disorder and upcoming approvals for pitolisant and Nefecon. - Phase III programs for selatogrel and cenerimod remain on track, suggesting pipeline readiness. - Overall, Viatris anticipates multiple product launches and regulatory milestones in 2026 supporting order growth and commercial momentum.